Eli Lilly Announces Acquisition of Ajax Therapeutics for $2 Billion

Key Stats for Eli Lilly Stock

• Price change for Eli Lilly stock: -2%
• $LLY Share Price as of Apr. 27: $868
• 52-Week High: $1,134
• $LLY Stock Price Target: $1,202

Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>

What Happened?

Eli Lilly (LLY) stock moved on news that the company agreed to acquire Ajax Therapeutics for up to $2.3 billion in cash.

The deal adds a promising early-stage blood cancer drug to Lilly’s oncology pipeline and continues a busy stretch of dealmaking for the pharma giant.

• Ajax’s lead drug, AJ1-11095, is an experimental once-daily oral treatment currently in early testing for myelofibrosis.
• That’s a rare blood cancer where scar tissue builds up in the bone marrow, disrupting normal blood cell production.
• The drug works by blocking JAK2, a protein that drives several blood cancers.
• What makes it different from existing treatments is how it binds to JAK2, which could make it more effective for patients who no longer respond to older drugs.
• Ajax is also developing the drug for polycythemia vera, a disorder where the body produces too many red blood cells. So there’s a potential path to multiple indications if the trials go well.

This isn’t a one-off bet. Lilly has been aggressively building its cancer portfolio, with recent acquisitions including Scorpion Therapeutics, Orna Therapeutics, and Kelonia Therapeutics. The Ajax deal fits squarely into that pattern.

Scotiabank analyst Louise Chen noted the deal builds on Lilly’s existing blood cancer capabilities and helps diversify its pipeline beyond obesity, which has been the main growth story for Eli Lilly stock in recent years.

The $2.3 billion includes an upfront payment plus additional milestone payments tied to clinical and regulatory progress.

See analysts’ growth forecasts and price targets for Eli Lilly stock (It’s free) >>>

What the Market Is Telling Us About Eli Lilly Stock

Lilly’s core business is in excellent shape.

• Full year 2025 revenue grew 45%, and earnings per share jumped 86%.
• The company is guiding for $80 to $83 billion in revenue in 2026, with orforglipron, its oral GLP-1, set to launch in Q2.

Against that backdrop, Eli Lilly stock has room to absorb a deal of this size comfortably.

Investors watching Eli Lilly stock closely will want to track how AJ1-11095 performs in early trials, since the upside here is entirely pipeline-dependent for now.

Estimate a company’s fair value instantly (Free with TIKR) >>>

How Much Upside Does Eli Lilly Stock Have From Here?

With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.

All it takes is three simple inputs:

1. Revenue Growth
2. Operating Margins
3. Exit P/E Multiple

If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.

From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.

See a stock’s true value in under 60 seconds (Free with TIKR) >>>

Looking for New Opportunities?

• See what stocks billionaire investors are buying so you can follow the smart money.
• Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
• The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.

Disclaimer:

Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!